Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other equities analysts have also issued reports on ALNY. JPMorgan Chase & Co. lowered their target price on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday. HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Oppenheimer reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Truist Financial dropped their target price on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $402.67.

Alnylam Pharmaceuticals Stock Up 7.2%

NASDAQ:ALNY opened at $220.33 on Friday. The firm’s 50-day moving average price is $286.42 and its 200-day moving average price is $309.85. The company has a market capitalization of $29.48 billion, a PE ratio of 40.95 and a beta of 0.30. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals has a 1-year low of $197.81 and a 1-year high of $495.55.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $25,000. HM Payson & Co. purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $27,000. Golden State Wealth Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $29,000. Finally, Manchester Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Raymond James upgraded Alnylam to “strong buy” and set a $420 price target, implying substantial potential upside from the referenced share price. The bullish call provides support for the stock despite its recent decline from prior highs. Raymond James upgrade
• Positive Sentiment: Chardan Capital reiterated its buy rating, reinforcing the view among some analysts that Alnylam’s growth prospects remain attractive. Chardan Capital buy rating
• Neutral Sentiment: Several firms reduced their price targets but maintained bullish ratings. Barclays lowered its target to $450 while keeping an “overweight” rating; Citigroup cut its target to $340 but retained a “buy” rating. Wells Fargo, Stifel and RBC also reduced targets to $316, $318 and $350, respectively. The cuts suggest more cautious valuation assumptions, although the ratings and targets remain positive. Analyst price-target changes Wells Fargo price target
• Neutral Sentiment: Other analysts have become more cautious. Morgan Stanley lowered its expectations, Oppenheimer issued a pessimistic forecast, and Wall Street Zen downgraded the stock to “hold.” These actions add pressure to the broader analyst outlook, which is mixed despite several high price targets. Morgan Stanley outlook
• Negative Sentiment: Two law firms announced continuing investigations into possible securities-law violations involving Alnylam. The notices invite shareholders who experienced losses to contact the firms. Although these announcements do not establish wrongdoing, they create potential legal, reputational and financial risks for ALNY. Frank R. Cruz investigation SBS Law investigation

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.